Ligandrol (LGD-4033) is categorized as a SARM. LGD has the capability to bind to the AR (androgen receptor) with an extremely high affinity. LGD is generally classified as an AR ligand that is tissue selective. It was originally developed to treat muscle wasting in cancer patients, age-related muscle loss as well as acute and chronic illness.
Ligandrol does come with side effects, although they have shown to be minimal through studies. Suppression from LGD-4033 can occur in minimal increments. Studies have shown this to be dose dependent but there has also been a decrease in total and free testosterone levels as well as SHBG levels. Intriguing findings through studies revealed no significant decrease in LH or FSH levels. This finding is very encouraging as it proves that although mildly suppressive, recovery will be short and sweet. LGD is non methylated and contains no toxicity. LGD does not convert to estrogen but in rare circumstances, has caused slight estrogen irritation for very few research subjects. An aromatase inhibitor should always be on hand, even if circumstances are rare. As with other sarms, a mini post cycle therapy is all that is needed with 2-3 weeks being the expected recovery time.
